Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Liraglutide and Tirzepatide — mechanism, side effects, legal status, and pricing.
Liraglutide is an FDA-approved GLP-1 receptor agonist marketed as Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). It was the first GLP-1 analog approved for obesity and carries an FDA boxed warning for the risk of thyroid C-cell tumors. Pediatric indications include type 2 diabetes in patients ≥10 years (Victoza) and obesity in patients ≥12 years with BMI ≥95th percentile (Saxenda).
Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It has a half-life of approximately 5 days, allowing once-weekly subcutaneous dosing.
Liraglutide
Tirzepatide
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Liraglutide
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check Liraglutide prices →Tirzepatide
COA corpus from Disclosed Labs — independently tested batches only.
Liraglutide
No COA data yet.
Submit testing data →Tirzepatide
306
COAs
99.7%
Avg purity
15
Labs
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015; PMID 26132939) demonstrated ~8% body-weight loss at 3.0 mg daily over 56 weeks, and the SCALE Diabetes trial (Davies et al., JAMA 2015; PMID 26284720) showed 6.0% weight loss in adults with type 2 diabetes. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; PMID 27295427) demonstrated a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes with established CVD or high CV risk. A pediatric Phase 3 trial (Kelly et al., NEJM 2020; PMID 32233338) supported Saxenda's FDA approval for adolescents ≥12 years with obesity. While less effective than newer GLP-1 agonists for weight loss, liraglutide has the longest track record and most extensive real-world safety data. The daily dosing requirement is its main disadvantage versus weekly semaglutide.
Key references
The SURPASS program established efficacy in type 2 diabetes, including SURPASS-2 (Frias et al., NEJM 2021), in which tirzepatide was superior to semaglutide 1 mg for A1C reduction and body weight. The SURMOUNT-1 obesity trial (Jastreboff et al., NEJM 2022) demonstrated up to approximately 20.9% mean body-weight reduction at 15 mg over 72 weeks. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed large reductions in apnea-hypopnea index in obstructive sleep apnea with obesity, supporting the 2024 FDA indication (Zepbound for moderate-to-severe OSA in adults with obesity). The SUMMIT trial (Packer et al., NEJM 2025) demonstrated a lower risk of cardiovascular death or worsening heart failure in HFpEF with obesity.
Key references
Liraglutide and Tirzepatide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs